Cellyan Biotechnology Co., Ltd (HKPD) Stock Score, Valuation & Financial Research
Cellyan Biotechnology Co., Ltd is in the Healthcare sector and Medical - Distribution industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 42/100.
Quick answer for HKPD
Cellyan Biotechnology Co., Ltd currently has a Wall Street Score of 42/100. The stored market price is $0.12. Its financial score is 53/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Cellyan Biotechnology Co., Ltd does
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
HKPD financial snapshot
- Wall Street Score:
- 42/100
- Current price:
- $0.12
- Market capitalization:
- $1.3M
- Revenue:
- $37.1M
- Net income:
- $1.2M
- Free cash flow:
- $414K
- Cash:
- $191K
- Total debt:
- $2.3M
- EPS:
- -0.00
- Financial score:
- 53/100
- Valuation score:
- 0/100
- Revenue score:
- 76/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $414K, showing positive cash generation.
- The balance sheet shows $191K of cash versus $2.3M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 53/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HKPD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.